The price of RMTI is predicted to go up 5.05%, based on the high correlation periods with KELYA. The similarity of these two price pattern on the periods is 98.41%.
RMTI
KELYA
Up: 5.05%Similarity: 98.41%
RMTI Revenue Forecast
RMTI EPS Forecast
RMTI FAQs
What is RMTI revenue forecast for next quarter?
The market consensus for RMTI's revenue in the upcoming quarter is projected to be approximately $19.123M USD.
Rodman & Renshaw initiated coverage of Rockwell Medical with a Buy rating and $5 price target. Rockwell has been a leading provider of dialysis concentrates in the U.S. for over 20 years, supplying essential concentrates used in dialysis machines to help patients with kidney issues, the analyst tells investors in a research note. The firm says that with expected revenue of over $65M in 2025 and potential for further gross margin improvement, the company remains undervalued despite the challenges of heavy customer concentration risk.